Since venetoclax acts as an anti-tumor agent by competitively inhibiting the interaction between BCL-2 and proapoptotic proteins, it is very likely that this molecule affects lymphoma cells by regulating protein-protein interactions or protein functions, but not at the transcriptional level. Here, BCL2 is linked to neoplasm.